Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials

• मुख्य लेखकों: Yuqian Wang (लेखक), Sheng Li (लेखक), Juan Bai (लेखक), Xiaoxuan Cai (लेखक), Shunli Tang (लेखक), Peiyi Lin (लेखक), Qingmiao Sun (लेखक), Jianjun Qiao (लेखक), Hong Fang (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: SAGE Publishing, 2023-04-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F, and is a promising drug for patients with moderate-to-severe plaque psoriasis. Objectives: This study aimed to assess the efficacy and safety of bimekizumab in treating patients with...